Laboratory values adequate for patient to undergo surgery, including:
Screening laboratory values must meet the following criteria and should be obtained within 30 days (or 45 days if a biopsy is repeated) prior to study treatment:
Adequate organ function as indicated by laboratory values
Any of the following clinical laboratory values at the time of enrollment: (1) Absolute neutrophil count (ANC) <800/µL or (2) Platelets < 50,000/µL
Patient must have adequate organ function as indicated by the following laboratory values independent of transfusion within 2 weeks:
Laboratory values at the Screening Visit:
Must have the following laboratory values, obtained less than or equal to 7 days prior to registration:
Patients must have normal laboratory values as defined below:
Screening laboratory values must meet the following criteria:
Adequate organ function as defined by the following laboratory values at screening:
Impaired baseline organ function as evaluated by out-of-range laboratory values
Screening clinical laboratory values as specified below:
Adequate safety laboratory values:
Adequate organ function as determined by the following laboratory values:
Inadequate end organ function as defined by specified laboratory values
The following required Initial Laboratory Values should be obtained within 4 weeks of the start of treatment:
Subject has the following laboratory values at Screening:
Most recent laboratory values within 2 weeks prior to Week 1 Day 1 (W1D1) meet the following standards:
Inadequate organ and marrow function as demonstrated by any of the following laboratory values. Transfusions intended to elevate any parameters below solely for the intent of meeting study eligibility are not permitted.
Subject has adequate organ function as determined by the following laboratory values:
Adequate hematologic and organ function as confirmed by laboratory values
Adequate hematologic and organ function as confirmed by laboratory values
Laboratory values must be no older than seven (7) days prior to the start of therapy; if a test that is repeated after registration and prior to therapy is outside the limits for eligibility, it must be rechecked within 48 hours prior to the start of therapy; if laboratory values still fail to meet eligibility criteria, the patient may not receive protocol therapy
Abnormal clinical laboratory values within 14 days prior to initiation of dosing, as indicated by:
Clinical laboratory values as specified below within 4 weeks before the first dose of study drug:
Patient has adequate bone marrow and organ function as defined by ALL of the following laboratory values (as assessed by local laboratory):
Impaired hepatic or renal function as demonstrated by any of the following laboratory values:
Screening chemistry values of the following:
Adequate clinical laboratory values defined as:
Adequate baseline laboratory values collected within 7 days of starting the study treatment
Patients with abnormal laboratory values, defined as any of the following:
Patient has adequate organ function, as indicated by the following laboratory values
Have laboratory values (obtained ? 28 days prior to first infusion day) in accordance with the study protocol
Adequate organ function as determined by the following laboratory values:
Adequate organ function as indicated by the following laboratory values. All laboratory tests must be obtained within 7 days prior to the first dose of study treatment:
Serum biochemical values with the following limits unless considered due to leukemia:
Adequate baseline laboratory values collected no more than 7 days before starting study treatment
Clinical laboratory values as specified in the following:
Serum biochemical values with the following limits unless considered due to leukemia:
Adequate clinical laboratory values defined as:
The following laboratory values must be documented within 3 days prior to the first dose of study drug:
Any of the following abnormal laboratory values (unless any of these abnormalities are due to underlying lymphoma)
Screening chemistry values of the following:
Patient must meet required laboratory values at the screening
Patient's clinical laboratory values meet any of the following criteria within the 7 days prior to Study Day 1:
-  Laboratory values (liver, kidney and hematology laboratory values) that meet criteria as described per protocol.
Screening laboratory values:
RENAL COHORT: Laboratory values as follows within 4 days before the first dose of daratumumab: platelets ? 100,000/mm^3
RENAL COHORT: Laboratory values as follows within 4 days before the first dose of daratumumab: hemoglobin ? 9 g/dL
RENAL COHORT: Laboratory values as follows within 4 days before the first dose of daratumumab: serum albumin ? 2.8 g/dl
RENAL COHORT: Laboratory values as follows within 4 days before the first dose of daratumumab: calcium ? LLN
RENAL COHORT: Laboratory values as follows within 4 days before the first dose of daratumumab: potassium ? LLN
BLADDER: Clinical laboratory values at screening: platelets ? 100,000/mm^3
BLADDER: Clinical laboratory values at screening: hemoglobin ? 9 g/dL
BLADDER: Clinical laboratory values at screening: serum albumin ? 2.8g/dl
Adequate laboratory values;
Adequate hematologic and organ function as confirmed by laboratory values
Clinical laboratory values within acceptable ranges within 72 hours prior to study day
Subject has the following laboratory values at screening:
Clinical laboratory values:
Adequate hematologic and organ function as confirmed by laboratory values
Abnormal laboratory values (unless due to underlying lymphoma)
Subject must have adequate organ function as indicated by the following laboratory values in the table below:
Screening clinical laboratory values:
Clinical laboratory values within the following parameters (repeat within 3 days before the first dose of study drug if laboratory values used for randomization were obtained more than 3 days before the first dose of study drug):
Baseline laboratory values as follows:
Any abnormal laboratory values as specified in protocol
Patients with the following laboratory values during screening and on Day 1 predose:
Subjects must have adequate organ function as indicated by the following laboratory values.
Subject has adequate organ function as determined by the following laboratory values:
Screening laboratory values must meet the following criteria and should be obtained within 30 days (45 if biopsy is repeated) prior to study treatment:
Clinical laboratory values:
Laboratory values as follows at screening and within 7 days of planned first dose of therapy:
Adequate organ function defined as follows: System and Laboratory Values: Hematologic
Any of the following clinical laboratory values at the time of enrollment:
The following laboratory values:
Patients with abnormal laboratory values during screening and on day 1 of pre-dose
Screening laboratory values should be used to confirm subject eligibility. Laboratory results may be retested if necessary to confirm eligibility.
The patient has adequate serum chemistry levels, evidenced by the following laboratory values
Clinical laboratory values as specified in the protocol
Laboratory values fulfilling the following:
Have adequate organ function as defined by specified laboratory values
Clinical laboratory values as specified in protocol
Patients with abnormal laboratory values as defined by the protocol
Laboratory values as specified in study protocol
Adequate organ functions as indicated by the following laboratory values (based on screening visit values from the central laboratory).
Laboratory values obtained ? 14 days prior to randomization:
Patients must have adequate organ function as indicated by the following laboratory values:
Clinical laboratory values as specified in the protocol Additionally, to be eligible for the Dose Expansion portion of the study:
Meeting the following laboratory values:
Laboratory values that would not prevent the patient from receiving chemotherapy as determined by the Principal Investigator (PI) or study oncologist
Adequate organ function, demonstrated by the following laboratory values:
Adequate organ function and baseline laboratory values
Systemic disease must be such that laboratory values are within 1.5 x normal
Adequate organ and hematological function as evidenced by the following laboratory values within 14 days before enrollment:
Adequate organ and hematological function as evidenced by the following laboratory values within 14 days before enrollment:
Any of the following baseline laboratory values:
Patients must have the following baseline laboratory values:
Adequate hematologic and organ function as confirmed by laboratory values at Screening:
All baseline laboratory requirements will be assessed and should be obtained within 14 days of first dose of study drug. Screening laboratory values must meet the following criteria:
Laboratory values and anticoagulation management per consensus guidelines, including:
Required screening laboratory values as described in the protocol
Patients with any of the following laboratory values at Screening/baseline
Laboratory values fulfilling the following:
Clinical laboratory values as specified below:
Clinical laboratory values as specified below within 3 days before the first dose of study drug:
Appropriate clinical laboratory values within 72 hours prior to study day 1:
Have adequate organ function as defined by specified laboratory values
Adequate clinical laboratory values during the screening period as specified in the protocol
Adequate clinical laboratory values during the screening period as specified in the protocol
Clinical laboratory values as specified within 14 days of treatment:
Patients must have the following clinical laboratory values:
Have adequate organ function as defined by specified laboratory values
Screening laboratory values:
Laboratory values fulfilling the following:
Patients must have clinical laboratory values meeting the following criteria within 28 days prior to registration:
Subject must have adequate organ function as indicated by the laboratory values below:
Patients whose laboratory values do not meet protocol criteria
Adequate organ function, as defined by the following criteria (per central or local laboratory values):
Adequate organ function as determined by the following laboratory values:
sustained clinically-significant worsening (investigator's assessment) from baseline granulocyte, platelet, or hemoglobin values (? 2 values, separated by ? 2 weeks)
Subjects must have the following laboratory values:
Subjects must have the following laboratory values at screening within 2 weeks of the first dose of investigational agents:
Most recent laboratory values (within 2 weeks prior to Week 1 Day 1 (W1D1)) before study entry meet the following standards:
Subjects must have the following screening laboratory values:
Clinical laboratory values and other measures as specified below within 28 days before the first dose of study drug:
Clinical laboratory values as specified below within 4 weeks before the first dose of study drug: